Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Moodys
AstraZeneca
Medtronic
Harvard Business School
Express Scripts

Last Updated: November 29, 2022

CLINICAL TRIALS PROFILE FOR CARDENE IN 0.86% SODIUM CHLORIDE IN PLASTIC CONTAINER


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


All Clinical Trials for Cardene In 0.86% Sodium Chloride In Plastic Container

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00325793 ↗ IV Double and Triple Concentrated Nicardipine for Stroke and ICH Unknown status PDL BioPharma, Inc. Phase 4 2004-01-01 Hypertension (high blood pressure) can often cause neurological worsening in patients with stroke, intracerebral hemorrhage and subarachnoid hemorrhage. Intravenous infusion of nicardipine (Cardene) for control of hypertension is FDA approved. The disadvantage of Nicardipine IV drip is the relative large volume of fluid needed (up to 150 cc/hr). The purpose of this study is to evaluate safety and efficacy of double or triple concentrated peripheral intravenous (IV) Nicardipine.
NCT00325793 ↗ IV Double and Triple Concentrated Nicardipine for Stroke and ICH Unknown status OSF Healthcare System Phase 4 2004-01-01 Hypertension (high blood pressure) can often cause neurological worsening in patients with stroke, intracerebral hemorrhage and subarachnoid hemorrhage. Intravenous infusion of nicardipine (Cardene) for control of hypertension is FDA approved. The disadvantage of Nicardipine IV drip is the relative large volume of fluid needed (up to 150 cc/hr). The purpose of this study is to evaluate safety and efficacy of double or triple concentrated peripheral intravenous (IV) Nicardipine.
NCT00528827 ↗ A Randomized, Double-blinded, Placebo-controlled, Dose-ranging Study of CardeneĀ® I.V. in Pediatric Subjects With Hypertension Withdrawn Facet Biotech Phase 2 2007-09-01 To define the relationship between Cardene I.V. dose, serum concentrations, and blood pressure reduction in pediatric subjects with hypertension.
NCT00765648 ↗ Evaluation of Intravenous Cardene(Nicardipine)and Labetalol Use in the Emergency Department Completed EKR Therapeutics, Inc Phase 4 2008-10-01 The purpose of this study is to compare the safety and efficacy of Cardene I.V. to labetalol administered intravenously for the management of hypertension in the emergency department setting.
NCT00765648 ↗ Evaluation of Intravenous Cardene(Nicardipine)and Labetalol Use in the Emergency Department Completed The Cleveland Clinic Phase 4 2008-10-01 The purpose of this study is to compare the safety and efficacy of Cardene I.V. to labetalol administered intravenously for the management of hypertension in the emergency department setting.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Cardene In 0.86% Sodium Chloride In Plastic Container

Condition Name

Condition Name for Cardene In 0.86% Sodium Chloride In Plastic Container
Intervention Trials
Hypertension 3
Cerebral Vasospasm 2
Acute Stroke 1
Endovascular Thrombectomy 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Cardene In 0.86% Sodium Chloride In Plastic Container
Intervention Trials
Hypertension 3
Cerebral Hemorrhage 2
Vasospasm, Intracranial 2
Stroke 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Cardene In 0.86% Sodium Chloride In Plastic Container

Trials by Country

Trials by Country for Cardene In 0.86% Sodium Chloride In Plastic Container
Location Trials
United States 17
Switzerland 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Cardene In 0.86% Sodium Chloride In Plastic Container
Location Trials
Illinois 2
Texas 2
Ohio 2
Florida 2
California 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Cardene In 0.86% Sodium Chloride In Plastic Container

Clinical Trial Phase

Clinical Trial Phase for Cardene In 0.86% Sodium Chloride In Plastic Container
Clinical Trial Phase Trials
Phase 4 5
Phase 2 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Cardene In 0.86% Sodium Chloride In Plastic Container
Clinical Trial Phase Trials
Withdrawn 3
Recruiting 2
Unknown status 1
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Cardene In 0.86% Sodium Chloride In Plastic Container

Sponsor Name

Sponsor Name for Cardene In 0.86% Sodium Chloride In Plastic Container
Sponsor Trials
Vanderbilt University Medical Center 2
University of Zurich 1
PDL BioPharma, Inc. 1
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Cardene In 0.86% Sodium Chloride In Plastic Container
Sponsor Trials
Other 21
Industry 4
NIH 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Express Scripts
Johnson and Johnson
Boehringer Ingelheim
Moodys
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.